- Cat. No.
- A11859
Fexofenadine HCl
Synonyms: Allegra
Fexofenadine HCl is an antihistamine that inhibits Cox-1, Cox-2, and is a histamine H1 receptor agonist
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Cyclooxygenase (COX) inhibitors block the first committed step in prostaglandin synthesis from arachidonic acid. COX-1 is expressed in most tissues, whereas COX-2 is induced by cytokines and growth factors during inflammation. In 1971, inhibition of prostaglandin synthesis was proposed as the mechanism of action of aspirin-like drugs. Crystal structures of COX-2 with bound inhibitors, reported in 1996, explained the structural basis of COX-2 selectivity. Nonsteroidal anti-inflammatory drugs (NSAIDs) in this category include indomethacin, ibuprofen and etodolac, which differ in their preference for the two isoforms. Licofelone inhibits both COX and 5-lipoxygenase (5-LOX), two branches of arachidonic acid metabolism. Acetaminophen, also known as paracetamol, is listed for research on prostaglandin signaling, pain and fever.
Synonyms: Allegra
Fexofenadine HCl is an antihistamine that inhibits Cox-1, Cox-2, and is a histamine H1 receptor agonist
Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions.
Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases.